The use of antibodies against the IL-2 receptor in transplantation.
Humanized monoclonal antibodies that recognize the alpha chain of the IL-2 receptor (e.g. daclizumab) have been used to prevent allograft rejection, since this chain is expressed by T cells participating in allograft rejection but not by resting T cells. In a randomized trial, when added to standard cyclosporin-based immunosuppression, daclizumab significantly reduced the frequency of acute rejection of renal transplants.
Waldmann
T A
TA
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. tawald@helix.nih.gov
O'Shea
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D004268:DNA-Binding Proteins / Q000235:genetics; D000077561:Daclizumab; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy; D015375:Receptors, Interleukin-2 / Q000276:immunology* / Q000502:physiology; D050797:STAT4 Transcription Factor; D015534:Trans-Activators / Q000235:genetics
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004268:DNA-Binding Proteins; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D050797:STAT4 Transcription Factor; C494090:STAT4 protein, human; D015534:Trans-Activators; D000077561:Daclizumab